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Simple Summary: Bile duct cancers are rare cancers that have poor prospects and limited treatment
options. Recently, significant advances have been made in the field of nanomedicine which has allowed
new approaches to the diagnosis and treatment (i.e., theranosis) of human diseases. To develop
nanomedicines that could earmark or target bile duct cancer, specific proteins (or biomarkers)
that are present in bile duct cancer but absent in normal tissues are required. We conducted a
systematic search of the published literature for bile duct cancer biomarkers that would be suitable
for theranosis. Specialist bioinformatics tools were used to help categorize the resulting data set.
To select the most promising biomarkers from the search, biomarkers were ranked according to a
theranosis-scoring-system and then evaluated in detail. The biomarkers identified using this approach
have the potential to promote targeted nanomedicine-based systems to treat bile duct cancers.
Abstract: Cholangiocarcinoma (CCA) is a rare disease with poor outcomes and limited research efforts
into novel treatment options. A systematic review of CCA biomarkers was undertaken to identify
promising biomarkers that may be used for theranosis (therapy and diagnosis). MEDLINE/EMBASE
databases (1996–2019) were systematically searched using two strategies to identify biomarker studies
of CCA. The PANTHER Go-Slim classification system and STRING network version 11.0 were used
to interrogate the identified biomarkers. The TArget Selection Criteria for Theranosis (TASC-T) score
was used to rank identified proteins as potential targetable biomarkers for theranosis. The following
proteins scored the highest, CA9, CLDN18, TNC, MMP9, and EGFR, and they were evaluated in
detail. None of these biomarkers had high sensitivity or specificity for CCA but have potential for
theranosis. This review is unique in that it describes the process of selecting suitable markers for
theranosis, which is also applicable to other diseases. This has highlighted existing validated markers
of CCA that can be used for active tumor targeting for the future development of targeted theranostic
delivery systems. It also emphasizes the relevance of bioinformatics in aiding the search for validated
biomarkers that could be repurposed for theranosis.
Keywords: biomarkers; cholangiocarcinoma; theranosis; therapy and diagnosis; biomarker selection
1. Introduction
Cholangiocarcinomas (CCA) are a group of cancers of the biliary system which are usually
diagnosed late, often with a dismal prognosis [1–4]. The most commonly used classification of CCA
Cancers 2020, 12, 2817; doi:10.3390/cancers12102817 www.mdpi.com/journal/cancers
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is anatomical and describes peripheral or intra-hepatic (iCCA), hilar or perihilar (pCCA), and distal
(dCCA); the latter two being subtypes of extra-hepatic CCA (eCCA) [2]. There is geographical
variation in the incidence of CCA with higher incidence in Eastern countries compared to Western
nations where this is a rare, sporadic cancer [5,6]. This cancer is especially prevalent in Thailand,
where CCA is a significant national health burden due to the prevalence of the liver fluke, which
is an etiological factor [7]. The only curative option for all subtypes involves aggressive surgical
resection with or without adjuvant therapy; however, only a minority are eligible [2,8]. In unresectable
disease, the median overall survival even with palliative chemotherapy remains less than twelve
months [9]. To improve these poor outcomes, discovery of new diagnostic markers, development of
targeted therapies to improve the translation of new strategies such as nanomedicine-based technology,
and predictive markers to determine response to therapy should be explored. There has been a recent
push towards the identification of genetic drivers of CCA progression and this may reveal specific
markers which could expedite the development of more effective and individualized therapies [10,11].
Theranostics is a new field of medicine that combines targeted therapies with diagnostics [12–14].
The term has been coined to define the ever evolving ‘precision medicine’ approach whereby diagnosis,
drug delivery and monitoring treatment response can be combined and tailored for each patient.
Over the last decade, significant advances have been made in the field of nanomedicine and its
potential applications for the diagnosis and treatment of human diseases [15–17]. Concomitant
use of nanoscale particles for theranosis has been evaluated in malignant and non-malignant
conditions [18–21]. Active tumor targeting to upregulated cancer cell receptors or tumor specific
markers by nanoparticles that have been surface-functionalized can potentially increase the specificity
of nanoparticle-based therapy. Active targeting relies on a “molecular ligand” that is upregulated
in tumor tissue compared to normal tissues to increase tumor specificity of nanoparticle uptake and
reduce off-site delivery/toxicity [22].
A recent systematic review on the application of active targeting nanoparticle delivery systems in
cancer therapy did not show any pre-clinical studies on CCA [23]. This reflects the general scarcity of
research efforts into novel therapeutics for this rare cancer.
Notable advances have been made in the discovery of biomarkers associated with CCA over
the last decade. In this study, we aimed to systematically interrogate the literature for published
studies in CCA for the purpose of identifying suitable biomarkers for active tumor targeting which in
future may aid in the development of a theranostic delivery platform combining molecular imaging
and therapeutic drug delivery. The methods used here may act as a blueprint to identify suitable
biomarkers for theranosis that are applicable to other cancers or disease states.
2. Materials and Methods
2.1. Systematic Search Strategy for Theranostic Biomarkers in CCA
The present review was conducted according to the Preferred Reporting Items for Systematic
reviews and Meta-Analyses (PRISMA) guidelines and recommendations. Electronic searches were
performed using MEDLINE/EMBASE from January 1996 to September 2019. Two strategies were used
to systematically search and identify immunohistochemical and proteomic biomarker studies of CCA
using the following search terms; Cholangio* OR Bile duct* OR Biliary tract OR Klatskin AND Cancer
OR Adenocarcinoma AND Immunohistoch* as well as Cholangio* OR Bile duct* OR Biliary tract
OR Klatskin AND Cancer OR Adenocarcinoma AND Proteome OR Proteomics. The search strategy
included all types of CCA biomarker studies (i.e., diagnostic, prognostic, predictive biomarkers, as well
as those comparing biomarkers between other liver tumors and disease states). The search identified
4560 studies. The PRISMA flow diagram shown in Figure 1 depicts the search strategy and the two
main search phases of this systematic review. Three authors (Imeshi Wijetunga (I.W), Laura E. McVeigh
(L.E.M) and Antonia Charalambous (A.C)) were involved in phases 1 and 2 of the screening and data
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extraction according to the agreed protocol. Any queries were resolved by discussion among I.W.,
L.E.M., and A.C.
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Figure 1. A flow diagram according to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) that maps the phases of the study selection process along with the number of
records identified, excluded studies and/or biomarkers (and the reasons for exclusion), and biomarkers
ultimately included in the systematic review.
2.2. Selection Criteria
Stage 1 of the screening process covered the titles and abstracts of the identified studies.
This revealed that 3859 did not meet the inclusion/exclusion criteria. The inclusion criteria used to
screen all identified articles were (1) all markers discovered in bile or tissue from CCA patients by
proteomic analysis and subsequently validated by immunohistochemistry (IHC) in at least 30 CCA
specimens or IHC studies that reported upregulation of biomarker (greater than 20% positive tumor
tissues and/or greater than 20% upregulation in tumor tissues), and (2) for IHC validation, the inclusion
of at least 30 iCCA/eCCA/pCCA specimens was required (similar to the cut off used by a recent
systematic review by Wiggers et al. [24]). The exclusion criteria applied to all identified studies were
(1) studies only involving cancer cell lines with no tissue validation; (2) circulating markers in blood
and urine were excluded unless they were also upregulated in the cancer tissue of origin by proteomic
or IHC methods; (3) upregulation in normal tissues (greater than 20% positive normal tissues in a
cohort and/or greater than 20% of normal tissues upregulation) as determined using Human Protein
Atlas [25]; (4) downregulated biomarkers in cancer tissue; and (5) review papers, letters, editorials,
conference abstracts, and case reports. All publications were limited to those involving human patients
and in the English language.
2.3. Data Extraction
For all included biomarkers, data were extracted on the study population demographics, tumor
site, reported percentage upregulation or percentage positive presence, subtypes of CCA included,
cellular location of tumor marker evaluated, whether tissue microarrays (TMAs) or whole sections
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were used, if a control group of tissues was included, percentage expression of biomarker in normal
tissues, number of investigators assessing tissue, and if they were independent and/or blinded.
2.4. Bioinformatics
The genes coding for the selected proteins were subjected to gene ontology analysis using
PANTHER GO-Slim classification system [26] and categorized based on the tissue compartment of
expression using the freely available online resource [27]. Biomarkers that were validated in two or
more studies were included in the final analysis and interrogated in more detail by targeted literature
searches. The STRING network (version 11.0) [28] was also used to further interrogate the final
shortlist of biomarkers for theranosis to ascertain any known associations between the more promising
biomarkers [29].
3. Results
3.1. Literature Search
A total of 701 studies, which included 1190 biomarkers, were selected for full text review
in stage 2 of the screening process (see Figure 1 for PRISMA flow diagram). This involved
evaluating each reported biomarker against the inclusion/exclusion criteria as well as scrutiny of the
Human Protein Atlas annotated protein level data for normal tissue presence of each biomarker [25].
One-thousand-and-twenty-four biomarkers were excluded for not meeting inclusion/exclusion criteria,
and the main reason for exclusion was the upregulation of the biomarker in normal tissues. In cases
where no annotated protein level data was reported in the Human Protein Atlas, biomarkers were
included in the data extraction unless the study reported upregulation in normal tissues which fulfilled
the exclusion criteria (i.e., greater than 20% positive normal tissues in cohort and/or greater than 20%
of normal tissues with upregulation).
One-hundred-and-sixty-six candidate biomarkers that met the inclusion/exclusion criteria were
identified and included in the data extraction table summarized in Table S1. Once replicate biomarkers
were excluded, 83 different biomarkers were identified, of which only 47 had annotated protein
level data reported in the Human Protein Atlas. Of these 47 biomarkers, only 16 were evaluated
in two or more biomarker validation studies and thus selected for further interrogation. These 16
included angiopoetin 1 (ANGPT1), angiopoetin 2 (ANGPT2), carbonic anhydrase 9 (CA9), cadherin 17
(CDH17), caudal type homeobox 2 (CDX2), Claudin 18 (CLDN18), epidermal growth factor receptor
(EGFR), matrix metalloproteinase 7 (MMP7), matrix metalloproteinase 9 (MMP9), alpha-1 antitrypsin
(SERPINA1), secreted frizzled related protein 1 (SFRP1), solute carrier family 2 member 1 (SLC2A1),
trefoil factor 1 (TFF1), transforming growth factor beta-1 (TGFB1), tenascin C (TNC), and p53 (TP53).
3.2. Gene Ontology of Selected Candidate Biomarkers
Figure 2 shows the PANTHER GO-Slim [30] classification of the 16 genes corresponding to the
identified proteins into the three gene ontology domains: molecular function, cellular component,
and biological process. Figure 2a categorizes the molecular function of the product of these genes.
Twelve out of sixteen are involved in binding such as protein binding, chromatin binding, heterocyclic
compound binding or ion binding. Four out of sixteen have catalytic activity either hydrolase (MMP9,
MMP7, and SERPINA1) or transferase (EGFR). Others such as SERPINA1 and TGFB1 are molecular
function regulators. In terms of cellular component, the majority of the gene products in the gene set
were present in the extracellular region (Figure 2b). EGFR, CDH17, SFRP1, and CLDN18 are present in
the plasma membrane.
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Figure 2. PANTHER classification of selected genes. PANTHER gene ontology classification of
16 selected genes based on (a) molecular function, (b) cellular component of expression, and (c)
involvement in biological processes. Large-scale gene function analysis protocol for PANTHER Version
14 classification system used for this analysis [30,31].
TP53 and CDX2 are transcription factors present in the nucleus. Twelve out of sixteen are involved
in cellular processes (Figure 2c) such as SERPINA1 and TGFB1 in cellular macromolecule metabolic
processes; MMP9 and MMP7 in cellular component organization; and ANGPT1, ANGPT2, EGFR,
and TP53 in signal transduction.
The PANTHER Version 14 Go-Slim categorization [30], which is a curated form of the entire
gene ontology database, did not include CA9, SLC2A1, and TNC. These were interrogated from the
PANTHER complete gene ontology database. In summary, CA9 has carbonate dehydratase activity,
is involv d i bicarbonate transp rt, and has membrane localization. SLC2A1 is transmembrane
glucose transporter, which is involved in res onse to hypoxi and also has a m mbrane loc lization.
TNC is an extracellular matrix structural protein that negatively regulates cell adhesion and is involved
in extracellular matrix organization.
3.3. Selection of Biomarkers for Theranosis
A scoring system for the selecti n of potentially t rgetable bi markers for imaging in colorectal
cancer (TArget Selection Criteria or TASC score) has been reported by van Oosten et al. [32]. However,
there are no published scoring tools for the selection of biomarkers incorporating a therapeutic aspect.
Despite overlap with imaging biomarker characteristics, theranostic biomarkers additionally require
very low or absent levels in normal tissue. A theranostic biomarker scoring system, which is a modified
version of the TASC score [32] named TASC-theranosis score (TASC-T), was therefore developed.
The sixteen selected candidate biomarkers were evaluated using TASC-T scoring criteria shown
in Table 1. Briefly, points of different weightage were awarded to each biomarker for the following
criteria; extracellular location, >20% positivity in tumor tissue, tumor to normal tissue level ratio >10,
percentage positivity or upregulation reported, previous application as an imaging or theranostic
biomarker either in pre-clinical or clinical studies, and if a ligand for the biomarker is available for
clinical use. All biomarkers included in this review scored 4 points automatically as >20% upregulation
was a selection criterion. The maximum score possible was 22 and biomarkers were considered
to have theranostic potential if they scored 17 or higher (similar to TASC score described by van
Oosten et al. [32]). Table 2 shows the TASC-T scoring for the 16 selected candidate biomarkers. A score
of 17 or higher was awarded to MMP9, CLDN18, TNC, CA9, and EGFR.
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Table 1. Potential targetable biomarkers for theranosis (TASC-T) scoring criteria.
No. Parameter Score
1 Extracellular or membrane localisation of biomarker 5
2 >20% positivity in tumor tissue 4
3 Tumor to normal tissue ratio >10 3
4
Percentage positivity or upregulation in tumor tissue
>90% 6
70–90% 5
50–69% 3
<49% 0
5
Previous application to imaging
Preclinical 1
Clinical 2
6 Ligand in human trials 1
Total 22Cancers 2020, 12, x  8 of 22 
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Table 2. TASC-T scoring of 16 selected biomarkers validated in ≥2 studies.
No. Tumor Biomarker Extracellular Membrane
Highest % Positivity/
Upregulation Reported in
CCA
Ligand in Human Trials
Previous Use in
Pre-Clinical or
Clinical Imaging
TASC-T (Max 22)
1 ANGPT1 Yes No 43.7 No No 9
2 ANGPT2 Yes No 57.6 No No 9
3 CA9 No Yes 85 Yes (Iodine-124 labeled cG250) Yes [33] 17
4 CDH17 No Yes 52.9 No No 15
5 CDX2 No No 60 No No 7
6 CLDN18 No Yes 90 Yes (Claudiximab, Zolbetuximab) No 19
7 EGFR Yes Yes 75 Yes (Cetuximab, Panitumumab) Yes [34] 17
8 MMP7 Yes No 80 No Yes [35] 15
9 MMP9 Yes No 67 Yes (Andecaliximab) Yes [36] 19
10 SERPINA1 Yes No 57 No No 12
11 SFRP1 Yes Yes 60 No No 12
12 SLC2A1 No Yes 52 No No 12
13 TFF1 Yes No 98.4 No No 15
14 TGFB1 Yes No 47 Yes (Fresolimumab) Yes [37] 15
15 TNC Yes No 63.9 Yes (Neuradiab, Tenatumomab) Yes [38] 18
16 TP53 No No 84 No Yes [39] 13
The STRING database version 11.0 [28] was used to ascertain any protein–protein interactions between the top five selected proteins as shown in Figure 3. This revealed that there are
associations between MMP9, CA9, and EGFR as well as TNC and EGFR in terms of being reported together in published studies. There was also evidence of co-presence of TNC and EGFR
as well as CA9 and EGFR. An experimentally determined association between TNC and EGFR has also been established. CLDN18, on the other hand, did not have any known associations
with the other four proteins being investigated.
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3.4. Selected Biomarkers for Theranosis in CCA
The biomarkers scoring 17 or higher in the TASC-T score, namely, MMP9, CLDN18, TNC, CA9,
and EGFR, were selected for in-depth analysis of their potential as theranostic biomarkers in CCA.
The study characteristics of the selected published studies of protein presence of these five biomarkers
in CCA are summarized in Table 3. Three out of these top five candidate biomarkers have only been
evaluated in two studies. Even in combination, CA9, CLDN18, and TNC have only been evaluated in
548 Eastern tissue specimens, 76% (417/548) of which were in iCCA tissues. MMP9 and EGFR have
been evaluated in multiple studies, but a wide range of positivity has been reported. This may be due
to difference is scoring methods. Although these two biomarkers have been evaluated in 1793 tissues
specimens in total, over 50% (936/1793) were evaluated in iCCA tissues only.
3.4.1. Matrix Metalloproteinase 9 Presence in CCA
Matrix metalloproteinase 9 (MMP9) has been evaluated in eight studies that met the
inclusion/exclusion criteria for this review [40–47]. Three-hundred-and-two iCCA and 334 eCCA
(including 120 pCCA tissue) have been evaluated with reported MMP9 positive ranges of 45.6 to 62.5%
and 47.3 to 58%, respectively. Only two studies commented on non-neoplastic biliary epithelium which
was reported as faint or absent [40,41]. All eight studies investigating MMP9 involve Eastern tissue
specimens from Korea, China, Japan, and Thailand. MMP9 scored 19/22 on the TASC-T score.
3.4.2. Claudin 18 Presence in CCA
Claudin 18 (CLDN18) was reported in two Japanese studies which included a total of 110 iCCA
tissues and 131 eCCA tissues [48,49]. Keira et al. [48] reported CLDN18 upregulation on the basolateral
surface of tissues with absence in the normal biliary epithelium. It was not possible to ascertain the
percentage positivity or upregulation in the 59 tissues included in this study. Shinozaki et al. [49]
reported 43% positive samples in 83 iCCA tissues and 90% positive samples in 99 eCCA tissues.
The annotated protein level of CLDN18 in normal tissues according to the Human Protein Atlas is
restricted to the stomach with an “enhanced” score for reliability, which is the highest awarded [25].
CLDN18 scored 19/22 on the TASC-T score.
3.4.3. Tenascin C Presence in CCA
Similar to CLDN18, Tenascin C (TNC) was also reported in two Japanese studies. However, all 109
tissue samples were from iCCA patients [50,51]. Neither of these studies described TNC in normal liver
tissue. The annotated protein level data of TNC is negative in all 44 tissues investigated by the Human
Protein Atlas [25] although the reliability of this pattern is “approved” which is one category higher
than the lowest “uncertain” category. Interrogating the primary data for the two TNC antibodies used
by the Human Protein Atlas, one (CAB004592, Santa Cruz Biotechnology) reported weak to moderate
immunoreactivity of most tissues but pancreas, liver, central nervous system, and lymphoid tissues
were negative. Immunoreactivity with the second antibody (HPA004823, Sigma-Aldrich) reported
strong positivity in seminiferous ducts and weak to moderate positivity in glandular epithelia. TNC
scored 18/22 on the TASC-T score.
3.4.4. Carbonic Anhydrase 9 Presence in CCA
Two studies [52,53] have explored Carbonic Anhydrase 9 (CA9) in CCA tissues which included 198
iCCA tissue samples in total and reported 85% upregulation in one study and 44.7% in the other (Table 3).
Neither of these studies commented on CA9 presence in adjacent normal liver tissue. No studies that
met the selection criteria for this review have evaluated CA9 in eCCA tissues. The annotated protein
level data of CA9 in normal tissues display moderate to upregulation in stomach, duodenum, small
intestine, and gall bladder [25]. CA9 scored 17/22 on the TASC-T score.
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Table 3. Study characteristics of the top five selected candidate biomarkers for theranosis in CCA.
Biomarker Country Site of Tumor No. % High/+ve Presence Normal Tissue Control Presence in Normal Tissues Risk of Bias References
MMP9 *
Multiple
(mainly Eastern)
iCCA 302 45.6–62.5% +ve
Normal liver tissue Weak or −ve Low-High [40–47]eCCA 214 47.3–58% +ve
pCCA 120 67.2–67.7% +ve
CLDN18
Japan iCCA 27 NR Biliary epithelium NR High [48]eCCA 32 NR
Japan iCCA 83 43% +ve Biliary epithelium −ve High [49]
eCCA 99 90% +ve
TNC
Japan iCCA 61 63.9% +ve NR NR High [50]
Japan iCCA 48 37.5% high NR NR High [51]
CA9
China iCCA 113 85.0% high NR NR Low [52]
Korea iCCA 85 44.7% +ve n = 4 normal liver NR High [53]
EGFR *
Multiple
(mainly Eastern)
iCCA 634 26.1–100% +ve
Normal liver tissue +ve membrane Low-High [50,54–67]
eCCA 402 18–79% +ve
pCCA 121 45.5% high
CCA 173 28.6–55% high
* Data amalgamated from multiple studies and range of protein presence for each CCA subtype shown. NR–not reported. +ve–Positive.
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3.4.5. Epidermal Growth Factor Receptor Presence in CCA
This review included 15 different studies which report Epidermal Growth Factor Receptor (EGFR)
presence in CCA [50,54–67]. Ten out of fifteen studies investigating EGFR involve Eastern tissue
specimens from Japan, China, Korea, and Thailand with 5/15 originating from USA, Brazil, Italy,
and Germany.
In 402 tissue specimens of iCCA, the reported positivity of EGFR ranged from 26 to 100%. Of the
634 eCCA specimens, 18–79% were reported as positive (Table 3). In 121 pCCA tissues and 173 CCA of
unspecified subtype, 28.6–55% of tissues were reported as positive. The proportion of CCA tissues
positive for EGFR is higher in iCCA compared to eCCA in the studies included in this review. This was
also the case in the four studies that included both iCCA and eCCA tissues and reported EGFR results
separately [56–58,61].
Of these 15 studies, only one study [57] commented on normal liver and biliary tract tissue
presence of EGFR as positive for EGFR immunoreactivity in all normal cholangiocyte and hepatocyte
membranes. Low levels of EGFR have been demonstrated in normal tissues such as liver, skeletal
muscle, and skin [25]. EGFR scored 17/22 on TASC-T.
4. Discussion
This review has highlighted that there have been a vast number of biomarker discovery and
validation studies in CCA. Herein, we describe a method of systematic review of literature for the
identification and selection of biomarkers for theranosis that is applicable to other cancers (Figure 4).
Although five biomarkers highlighted in this review have potential for being theranostic targets, most
of them lack robust tissue validation data in CCA. CA9, CLDN18, and TNC have only been validated
in two separate studies that met the inclusion criteria for this study, whereas MMP9 and EGFR have
been investigated by multiple research groups. We will now discuss the potential of each of the five
protein targets that could be used as a CCA biomarker for theranosis, describing previous relevant
studies and remarking on their suitability.
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4.1. Matrix Metalloproteinase 9
MMP9 upregulation and its negative association with prognosis in cancers such as gastric cancer
has been reported and a monoclonal antibody aimed at MMP9 inhibition is currently in human
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trials [68]. A clinical trial commenced in 2016 comparing andecaliximab (also known as GS-5745),
which is an MMP9 inhibitor, as monotherapy and in combination with anti-cancer agents in Japanese
participants with gastric or gastroesophageal junction adenocarcinoma is currently awaiting results
(ClinicalTrials.gov, NCT02862535). This is one of five completed trials that evaluated andecaliximab in
solid tumors, but none have yet published results. None of these trials included patients with CCA.
Although a humanized monoclonal antibody is available, to our knowledge there has not been any
human studies published using MMP9 as an imaging or theranostic biomarker. The structure of MMP
9 is shown in Figure 5a.
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present in the extracellular matrix (ECM). Schematic shows the different binding domains of MMP9.
(b) Claudin 18.2 is present in the tight junctions and cell membrane. Schematic shows the two predicted
extracellular loops and intracellular loop of Claudin 18.2. (c) Tenascin-C (TNC) is a large protein that
exists as a hexa er in the ECM. Schematic (on th left) showing the fi e different domains of TNC
from the N-terminus EGF-like repeats, fixed fibronectin domain, variable fibronectin domain, fixed
fibronectin domain, and C-terminus fibronectin head. Schematic on the right shows the TNC hexamer,
called hexabrachion. (d) CA9 is present in the cell membrane. (e) EGFR is present in the cell membrane.
Schematic shows the inactive form of EGFR which dimerises on binding of Epidermal growth factor
(EGF) to its active form.
Recently, Hakimzadeh et al. [36] developed a MMP9 and MMP2 targeted radiolabeled ligand for the
purpose of imaging atherosclerotic lesions. On ex vivo measurement of radioactivity, they demonstrated
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increased signal in mouse aortic tissue with atherosclerotic lesions and subsequently confirmed MMP9
and MMP2 immunoreactivity on these tissue sections. They described the radiolabeling procedure as
challenging with an insufficient yield of radiolabeled product [36]. This may be the reason the authors
do not report any in vivo imaging. Although this ligand may be useful for imaging MMP9 expressing
cancers, the lack of MMP9 specificity of the ligand could result in low signal-to-noise ratio, as MMP2
presence in normal tissues is more widespread compared to MMP9 [25].
None of the studies that met the inclusion/exclusion criteria for this review included patients
from Western cohorts. A previous study at our institution investigated MMP9 in 54 pCCA specimens
from a Western cohort of patients but this too did not meet the inclusion criteria for this study due to
all adjacent non-cancerous liver control tissues being MMP9 positive [69]. This is in contrast to the
reported low or negative normal liver tissue level reported by the Human Protein Atlas [25] and the
2/8 studies that reported low or absent MMP9 in normal biliary epithelium [40,41]. Whether this is due
to differences in tissue handling and immunohistochemical processing or whether this is non-specific
background labeling from the antibody utilized remains to be determined. If normal liver is indeed
truly positive, MMP9 is unlikely to be a good theranostic target despite being highlighted as a potential
candidate in this review.
4.2. Claudin 18
CLDN18 has two main alternate splice variants [70] of which the alternate splice variant 2
expression is mainly seen in gastric epithelium whereas variant 1 is observed in lung tissue [71].
Sahin et al. [72] reported that protein coded by CLDN18 splice variant 2, termed CLDN18.2, is present
in several cancers including gastric (77% positive), pancreatic (80% positive), and esophageal (78%
positive) cancers.
CLDN18.2 has been identified as a target suitable for therapeutic antibody development [72],
and CLDN18.2-inhibiting monoclonal antibodies (e.g., claudiximab and zolbetuximab) are now in
clinical trials for esophageal, gastric, and pancreatic adenocarcinoma. Two phase 3 trials using the
addition of zolbetuximab or placebo to standard chemotherapeutic regimens are currently recruiting
CLDN18.2 positive patients (ClinicalTrials.org: NCT03504397 and NCT03653507). However, a recent
large immunohistochemical study of gastric cancer in a cohort of Caucasian gastric cancer patients
only showed 42.2% (203/481) positive for the presence of CLDN18.2 [73].
Although published literature on CLDN18 in CCA is limited, one included study reported a
difference in the presence in iCCA compared to eCCA. Shinozaki et al. [49] demonstrated a 90% positive
presence in eCCA. Interestingly, other biomarkers present in gastric epithelium such as mucin 5AC
(MUC5AC), mucin 6 (MUC6), and cytokeratin 20 (KRT20) have also shown to be higher in eCCA
compared to iCCA [24].
The structure of CLDN18.2 as shown in Figure 5b has two predicted extracellular loops, the first
of which includes the binding site for claudiximab. Tight junction proteins exist in the lateral apical
surface between two epithelial cells. Whether the extracellular sites of tight junction proteins will
be accessible to systemically delivered theranostic agents is not known. In favor of CLDN18.2 as a
theranostic agent, in terms of its cellular location, it has been shown to be present throughout the cell
membrane in normal physiology [71] and not just restricted to tight junctions. This may also be the
case in cancerous cells as they are generally less tightly adherent to neighboring cells and have less
well organized cellular barriers compared to normal tissue.
4.3. Tenascin C
TNC is a large protein that exists as a hexamer in the extracellular matrix [74]. Although abundant
in embryonic tissues, its presence in adult tissues is limited to areas of inflammation, wound healing,
and tumor growth [75–77]. This restricted pattern and upregulation during tumor growth has made
TNC an attractive biomarker for developing targeted theranostics. Figure 5c shows a schematic of
TNC structure as a monomer and hexamer.
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This review has highlighted two studies which report TNC in iCCA. TNC in eCCA has not been
reported. However, TNC presence in gastrointestinal malignancies such as pancreatic ductal [78,79],
oesophageal [80], gastric [81], and colorectal [82] adenocarcinoma have been described.
With regard to TNC targeted imaging, Hicke et al. [83] demonstrated tumor targeting in a
glioblastoma xenograft model using a TNC-specific RNA aptamer. They were able to image U251
glioblastoma xenograft tissue in vivo with Technetium-99m-labeled TNC aptamers using radionuclide
imaging [83]. He et al. [84] developed a nanoparticle formulation of camptothecin prodrug conjugated
with a cell penetrating peptide and TNC-targeted single-stranded DNA aptamer and evaluated this in a
xenograft model of pancreatic ductal adenocarcinoma. They were able to demonstrate in vivo imaging
of these particles and demonstrated therapeutic response in a xenograft model [84]. These successful
applications of TNC-targeted theranostics using aptamers is promising as antibody mimetics have
several advantages over antibodies including their lower cost, scalability, and more ethical synthesis as
they do not require an intact host immune system for their production [85,86].
4.4. Carbonic Anhydrase 9
CA9 belongs to a large group of carbonic anhydrase enzymes which act as catalysts for the reversible
reaction of carbon dioxide with water to bicarbonate and hydrogen ions [87,88]. Although this family
of enzymes are ubiquitously expressed in humans, CA9 is restricted mainly to the gastrointestinal tract
further upregulation is seen in gastric cancer and several other solid tumors [88,89]. The role of CA9 in
the regulation of pH in the tumor microenvironment and induction of CA9 expression in response to
tumor tissue hypoxia has been demonstrated [90].
Given the restricted presence in normal tissues and upregulation in solid tumors, CA9 has gained
considerable interest as a novel tumor target [91]. Despite pre-clinical data supporting the use of CA9
inhibition as a therapeutic option for cancers, there have not been any human studies demonstrating
its benefit [92]. The results of a phase I clinical study of a CA9 inhibitor in solid cancers [93] is still to
be reported.
In addition to low normal tissue distribution and upregulation in cancer, CA9 as a potential
theranostic target has several other key advantages. It is a membrane-bound protein with an
extracellular catalytic component as shown inFigure 5d. This makes it easily “visible” to systemically
delivered theranostic agents without uptake into the cell. In addition, it has previously been used as an
imaging biomarker [33]. Binding to CA9 and internalization of positron emission tomography (PET)
tracers labeled with CA9 antibody have been demonstrated in a mouse xenograft model of renal cell
carcinoma [94]. The other feature that could be exploited is its enzymatic activity, which is a desirable
feature in an imaging [32] as well as theranostic biomarker. A theranostic agent that is intended to
target CA9 could be designed to be activated by CA9 thus releasing its drug payload only when it has
reached the tissue target.
Although restricted mainly to gastric mucosa, CA9 is present in normal tissue and has a role in pH
regulation [95], and thus the potential side effects of CA9 as a theranostic target have to be considered.
If this is to be explored in future in vivo studies, endpoint gastric mucosa histology should be assessed
for potential off-target toxicity. Another disadvantage of CA9 as a theranostic target is that its presence
in tumor tissues is induced by tissue hypoxia. If this is indeed the case, the delivery of a theranostic
particle to the site of CA9 will be challenging, as systemically administered agents are likely to have
low tissue penetration.
4.5. Epidermal Growth Factor Receptor
Extensive research efforts have been focused on EGFR over the past two decades and anti-EGFR
therapy in combination with conventional chemotherapy is now in routine practice for cancers
such as metastatic colorectal cancer (mCRC) [96]. Cetuximab, which is a human/mouse chimeric
monoclonal antibody, and the fully human monoclonal antibody panitumumab that inhibits EGFR
were approved by the Food and Drug Authority (FDA) of the United States in 2004 and 2006,
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respectively [97]. Either cetuximab or panitumumab in combination with first-line chemotherapy
has been evaluated in advanced biliary tract cancer (BTC) but neither has shown any significant
improvement in progression-free survival or overall survival [98]. This suggests that inhibiting the
EGFR pathway alone may not be beneficial or that it may be beneficial only in a subset of BTC, a
difference these clinical trials were not sufficiently powered to detect.
A schematic structure of EGFR both in its inactive form and its dimerized active form is shown
in Figure 5e. Cetuximab and panitumumab work by binding to a site on the extracellular domain of
EGFR that partly occludes the binding site for native epidermal growth factor (EGF) [99,100].
Noninvasive imaging of EGFR status has been investigated and several EGFR radiolabeled tracers
have been developed for PET and single-photon emission computed tomography (SPECT) [97,101].
In patients with mCRC, Van Helden et al. [101] were able to image tumor uptake of cetuximab labeled
radiotracer, but this was not directly correlated with EGFR presence and did not predict treatment
benefit with cetuximab. One confounding factor in this study was the pre-treatment of patients with
unlabeled cetuximab to occupy non-malignant binding sites as invariably EGFR binding sites on the
tumor could also be saturated which would have had an impact on subsequent imaging. This highlights
that an ideal theranostic biomarker should have low or negative presence in normal tissues. In this
ideal scenario where the presence of the biomarker of interest is truly negative in normal tissues,
pretreatment would be unnecessary.
This review has highlighted 15 studies reporting the presence of EGFR in CCA. Although the
scoring methods differed between studies, there was a trend towards upregulation of EGFR in iCCA
compared to eCCA. This was still the case when only the four studies that reported EGFR in both iCCA
and eCCA were considered [56–58,61]. This may suggest that EGFR may not be a useful theranostic
maker in eCCA.
4.6. Challenges and Limitations
This systematic review highlighted the challenges and limitations of this type of study.
The heterogeneity of the CCA biomarker studies and the scarcity of biomarker validation in multiple
centers hampers the conclusions that can be drawn and makes meta-analysis of data impossible.
The studies encountered in this review were mainly aimed at biomarker discovery of diagnostic,
predictive, or prognostic biomarkers in CCA or those that could be direct therapeutic targets which
were not always suitable candidates as theranostic biomarkers.
The five biomarkers described in detail in this study have theranostic potential in CCA as they
can have both in vivo diagnostic (e.g., molecular imaging, mapping tumor margins and/or sites of
metastatic disease) and therapeutic (e.g., targeted drug delivery using nanotechnology) applications.
However, they are not CCA-specific, not necessarily detectable in body fluids such as blood or urine,
and would not fulfill the role of early diagnostic biomarkers in the traditional sense.
The studies included often discussed proteins using different aliases, and therefore gene names
had to be used to ensure that the data were extracted for the correct protein. Furthermore, there was
significant variability in reporting of the results and scoring methods for the same biomarker making
a comparison across studies very difficult. Often supplementary data was required to extract the
necessary data and infrequently, studies had to be excluded as the percentage positive presence or
upregulation in tissues could not be determined from the data provided.
The majority of studies involving histology specimens were performed in Eastern countries such
as Thailand and Japan where CCA has a higher incidence due to etiological differences [6]. Although
this geographical difference reflects the relative disease burden of CCA worldwide, the scarcity of
tissue from Western cohorts makes it difficult for conclusions to be drawn about the applicability
of these biomarkers for CCA theranosis in general. Hughes et al. [102] explored the differences in
cell phenotypes in a cohort of liver fluke associated CCA (65 cases) in comparison to sporadic CCA
(47 cases). They reported that liver fluke-associated CCA had more intestinal metaplasia phenotypes
and was more likely to overexpress p53 in comparison to sporadic CCA. Whether other biomarkers
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expressed in liver fluke associated CCA are comparable to those in sporadic CCA and CCA that arises
on a background of PSC seen in Western countries remains to be explored.
An attempt was made to assess the risk of bias of the studies including consideration of the
criteria of the Newcastle–Ottawa Scale [103]. However, due to significant heterogeneity the only
measure of bias that was included in the data extraction was the assessment of tissue. Studies were
regarded as low bias if two or more blinded investigators independently scored the tissue sections.
A significant proportion of studies did not utilize appropriate control tissues in parallel with CCA tissue
for biomarker analysis, which was a significant deficiency. Where normal tissue controls were included,
the immunolabeling pattern in normal bile duct tissue and hepatocytes lacked detailed description.
Although the Human Protein Atlas [25] was an exceedingly useful resource, 43% (36/83) of the
potential candidate biomarkers did not have annotated protein level data in normal tissues. Even for
those proteins that did, the reliability score was variable. The reliability score ranged from “enhanced”,
“supported”, and “approved” to “uncertain”, reflecting the immunohistochemical data available using
one or more antibodies as well as the RNA sequencing data [25]. Despite this, no biomarker was
excluded based on the reliability score.
While guidance exists on reporting outcomes from tumor biomarker prognostic studies for
IHC-based studies, i.e., REMARK guidelines [104], no such guidelines exist for tumor biomarkers in
general. Therefore, the studies included in this review display significant deficiencies in reporting.
Such guidance for reporting of all biomarker studies would result in a more consistent data set and
hence improve the likelihood that these studies will have a wider impact on translational research.
We recommend reporting presence of the candidate biomarkers in adjacent non-tumor tissue in all
studies. We also recommend reporting of the cell type and cellular compartment where expression
is observed. Another important aspect of reporting is the subtype of CCA from which the tissues
originate as immunohistochemical differences have been observed in iCCA and eCCA [24].
The quest for ideal biomarkers that are specific to CCA tissue, which could then be actively
targeted by drug-loaded nanoparticles, is still in its infancy. Given the heterogeneity of biomarker
expression and the various anatomical and histological subtypes of CCA, individualizing the treatment
strategy to develop customizable theranostic agents may be the way forward.
Two out of the five biomarkers (CLDN18 and CA9) highlighted in this review have also been
reported as potential theranostic targets in gallbladder cancer [105]. EGFR and MMP9 have long been
areas of research focus in cancer theranostics. TNC has also gained popularity as a biomarker for
cancers as well as other conditions such as cardiovascular disease [106].
As demonstrated by this review, these five biomarkers with potential for theranosis in CCA
have cross-specialty therapeutic uses allowing a broader application than just cancer for any
theranostic nano-agent.
5. Conclusions
Here, we describe a method for systematic review of literature for the identification of theranostic
biomarkers and assessment of biomarker characteristics according to their theranostic potential
which involves the utilization of freely available bioinformatics tools to gather validated information.
This method of identification and validation of theranostic biomarkers is therefore more widely
applicable to other cancers and disease states. It is important to note that a high proportion of
biomarkers identified in this systematic review dealt with those investigated for their prognostic
value, which reflects the current published literature and perhaps a publication bias towards such
studies in cancer. An early diagnostic biomarker that is also a therapeutic delivery target would be an
ideal theranostic biomarker, and thus future research should concentrate on biomarker discovery of
such biomarkers.
The five biomarkers with theranostic potential in CCA that were identified in this review have
cross-specialty therapeutic applications. Knowing the scale of resources required to develop, validate,
and translate biomarkers to clinical practice, collaborative efforts from different research groups will be
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essential in the future. The need for continued efforts to develop novel therapeutic strategies cannot be
overemphasized for this rare group of cancers that have rising global incidence.
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